MARKET

SNGXW

SOLIGENIX WT
SNGXW
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-0.1896
0.1049
0.0255
-
Soligenix Inc. unveils pipeline progress and rare disease treatment strategies in new corporate presentation
Reuters · 11/24 17:52
Soligenix Reaches Interim Enrollment Milestone in Phase 3 HyBryte Trial for CTCL
Reuters · 11/19 12:30
SOLIGENIX ACHIEVES ENROLLMENT MILESTONE FOR PLANNED INTERIM ANALYSIS IN CONFIRMATORY PHASE 3 CLINICAL TRIAL OF HYBRYTE™ FOR THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA
Reuters · 11/19 12:30
Soligenix Regains Nasdaq Compliance After Equity Shortfall
Reuters · 11/18 21:06
Biopharma firm Soligenix's Q3 net loss widens on increased R&D spends
Reuters · 11/07 12:40
Soligenix Reports Net Loss of $2.5 Million With No Revenue in Q3 2025
Reuters · 11/07 12:31
SOLIGENIX ANNOUNCES RECENT ACCOMPLISHMENTS AND THIRD QUARTER 2025 FINANCIAL RESULTS
Reuters · 11/07 12:30
SOLIGENIX Q3 NET INCOME USD -2.5 MILLION
Reuters · 11/07 12:30
More

Webull offers SOLIGENIX WT stock information, including NASDAQ: SNGXW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNGXW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNGXW stock methods without spending real money on the virtual paper trading platform.